Antimycobacterial therapy for disseminated Mycobacterium avium complex infection in patients with acquired immunodeficiency syndrome.

Department of General Internal Medicine, Veterans Affairs Hospital, University of California, San Francisco 94143-0320.
Archives of Internal Medicine (Impact Factor: 13.25). 05/1992; 152(4):813-7.
Source: PubMed

ABSTRACT BACKGROUND--Antimycobacterial therapy for disseminated Mycobacterium avium complex (DMAC) in patients with acquired immunodeficiency syndrome (AIDS) may ameliorate symptoms and decrease bacteremia. However, no studies have demonstrated improved survival in patients with AIDS treated for DMAC. We assessed the effects of treatment of DMAC on the survival of patients with AIDS. METHODS--We retrospectively reviewed records of patients with AIDS and DMAC seen at two San Francisco, Calif, hospitals between January 1, 1988, and January 1, 1990. The treatment group (N = 76) consisted of patients who received 2 weeks or more of antimycobacterial therapy with at least three agents. The untreated group (N = 74) received either no therapy or isoniazid alone. Patients in both groups lived a minimum of 2 weeks after the diagnosis of DMAC. RESULTS--The median survival in the treatment group was 191 days, compared with 80 days in the untreated group. In a multivariate proportional hazards model (N = 145), both treatment of DMAC (relative hazard = 0.34; 95% confidence interval, 0.23 to 0.51) and treatment with zidovudine (relative hazard = 0.54; 95% confidence interval, 0.36 to 0.82) were associated with improved survival. CONCLUSION--Patients with AIDS and DMAC who are treated with antimycobacterial drugs may survive longer than untreated patients. We recommend that a randomized trial be conducted to evaluate the optimal treatment of DMAC.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of disease caused by Mycobacterium avium complex (MAC) in HIV-infected individuals has undergone considerable evolution over the past 15 years. Agents with known antimycobacterial activity such as rifampin/rifabutin, ethambutol, and clofazimine, as well as others such as amikacin, liposome-encapsulated gentamicin, several of the fluoroquinolones (ciprofloxacin, ofloxacin, and sparfloxacin), and the new macrolides, azithromycin and clarithromycin, have all been used with varying degrees of success. Of all these agents, the macrolides have clearly had the biggest impact to date on the management of disseminated MAC. Studies of both azithromycin and clarithromycin in short-term monotherapy trials have corroborated their clinical and microbiological efficacy. The risk of drug resistance with monotherapy, however, has prompted investigation of combination regimens for the treatment of MAC. A recent study of a three-drug, clarithromycin-based regimen versus a four-drug regimen without clarithromycin has shown that patients treated with the regimen containing clarithromycin had significantly greater overall symptomatic improvement, more rapid and significant clearing of mycobacteremia, and improved survival. Results from studies of combination regimens with azithromycin should be available soon. Although there is still no “regimen of choice,” initial treatment with at least two active agents, one of which should be either azithromycin or clarithromycin, is the currently recommended approach; the majority opinion favors ethambutol as the preferred second agent. Use of adjunctive therapies and more potent antiretroviral regimens may also play a role.
    The American Journal of Medicine 05/1997; 102(5):16-21. DOI:10.1016/S0002-9343(97)00039-9 · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The improvement of survival of AIDS patients allowed the emergence of disseminated Mycobacterium avium Complex infections (D.MAC). Here we report the experience of the group of “Épidemiologie clinique du sida en Aquitaine (GECSA)“ about 100 patients. There were no differences according to sex, age and route of acquisition of HIV. Clinical and biological characteristics of the infections were not specific. The mean TCD4+ lymphocytes count was 18/mm3 . The diagnostic was generally established by systematic blood culture on Septi-Chek in patients with TCD4+ lymphocytes count below 75/mm3. The recommendations on therapy for D.MAC are to use regimen containing azithromycin or clarithromycin, ethambutol and one of the following drugs, rifabutin, clofazimine, amikacin, or ciprofloxacin. Rifabutin is recommended for prophylaxis in patients with lymphocytes TCD4+ count below 100/mm3 .
    La Revue de Médecine Interne 02/1995; 16(2):110-120. DOI:10.1016/0248-8663(96)80675-8 · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mycobacterium avium complex (MAC) is a common environmental organism. Disease in humans due to this organism is primarily manifested by three clinical syndromes: disseminated disease, usually in persons with advanced human immunodeficiency virus (HIV) infection; pulmonary disease, in persons whose systemic immunity is intact; and cervical lymphadenitis, also a disease of normal hosts. Disseminated disease in persons with AIDS is the most common clinical presentation, and all three syndromes are increasing in frequency. Research is needed to identify the environmental reservoirs and modes of acquisition leading to MAC disease in humans and to explain recent increases in occurrence.
    The American Journal of Medicine 05/1997; 102(5):11-15. DOI:10.1016/S0002-9343(97)00038-7 · 5.30 Impact Factor